Cell Genesys: GVAX Treatment Safe, Well Tolerated
Monday June 2, 12:24 pm ET
SOUTH SAN FRANCISCO (Dow Jones)--Cell Genesys Inc. said two patients had complete responses in Phase I/II trials of its GVAX cancer vaccine for multiple myeloma, a type of bone marrow cancer.
In a press release Monday, Cell Genesys said the results are encouraging and support the evaluation of GVAX vaccines in other blood cancers such as acute leukemia.
In the study, 14 patients with advanced myeloma were treated with chemotherapy and then received bone marrow stem cell transplantation and a GVAX vaccination.
The stem cell and GVAX combination resulted in two complete reponses, six partial responses, two patients with stable disease, one patient with disease progression and three patients that aren't yet evaluable.
The GVAX treatment to date has been safe and well tolerated, Cell Genesys said.
The company presented its data at the American Society of Clinical Oncology meeting in Chicago. Biotechnology stocks have been rallying Monday following a string of positive data on cancer drugs.
Cell Genesys' Nasdaq-traded shares, however, recently fell to $10.64, down 62 cents, or 5.5%, on composite volume of 725,483 shares. Average daily volume is 315,181 shares.
-Kara Wetzel; Dow Jones Newswires; 201-938-5400 |
